| Literature DB >> 34630596 |
Ahmet Önder Porsuk1, Çiğdem Cerit2,3.
Abstract
BACKGROUND: In Turkey, an increase of scabies cases was detected since the last quarter of 2019. During the same period, Turkey was also under the influence of the COVID-19 pandemic affecting the whole world. This study aimed to determine the current situation of scabies cases in increasing incidence during COVID-19 pandemic days and to create a scientific resource for the measures to be taken.Entities:
Keywords: COVID-19 pandemic; Scabies; Turkey
Year: 2021 PMID: 34630596 PMCID: PMC8476727 DOI: 10.18502/ijpa.v16i3.7104
Source DB: PubMed Journal: Iran J Parasitol ISSN: 1735-7020 Impact factor: 1.012
Scabies cases by years
|
|
|
|
|
|
|---|---|---|---|---|
| 2017 | 356.050 | 249 | 69,9 | <0.001 |
| Variation (n, %) | 4.810 (1,4) | 19 (7,6) | 4,4 | |
| 2018 | 360.860 | 268 | 74,3 | |
| Variation (n, %) | 970 (0,3) | 434 (161,9) | 119,7 | |
| 2019 | 361.836 | 702 | 194,0 | |
| 2020 (First Six Months) | - | 619 | - | - |
Since the population of the first six months is unknown, the incidence has not been calculated.
The distribution of cases by years and age groups
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
| |
| 0–4 | 5 (2.0) | 10 (3.7) | 30 (4.3) | 21 (3.4) | 66 (3.6) | |||||
| 5–9 | 8 (3.2) | 10 (3.7) | 30 (4.3) | 17 (2.7) | 65 (3.5) | |||||
| 10–14 | 17 (6.8) | 14 (5.2) | 41 (5.8) | 33 (5.3) | 105 (5.7) | |||||
| 15–19 | 28 (11.2) | 22 (8.2) | 51 (7.3) | 54 (8.7) | 155 (8.4) | |||||
| 20–24 | 34 (13.7) | 64 (23.9) | 103 (14.7) | 107 (17.3) | 308 (16.8) | |||||
| 25–29 | 20 (8.0) | 21 (7.8) | 64 (9.1) | 47 (7.6) | 152 (8.3) | |||||
| 30–34 | 16 (6.4) | 12 (4.5) | 44 (6.3) | 28 (4.5) | 100 (5.4) | |||||
| 35–39 | 17 (6.8) | 13 (4.9) | 62 (8.8) | 40 (6.5) | 132 (7.2) | |||||
| 40–44 | 22 (8.8) | 15 (5.6) | 49 (7.0) | 38 (6.1) | 124 (6.7) | |||||
| 45–49 | 11 (4.4) | 11 (4.1) | 44 (6.3) | 43 (6.9) | 109 (5.9) | |||||
| 50–54 | 15 (6.0) | 8 (3.0) | 32 (4.6) | 36 (5.8) | 91 (5.0) | |||||
| 55–59 | 14 (5.6) | 15 (5.6) | 42 (6.0) | 30 (4.8) | 101 (5.5) | |||||
| 60–64 | 12 (4.8) | 12 (4.5) | 35 (5.0) | 33 (5.3) | 92 (5.0) | |||||
| 65–69 | 13 (5.2) | 13 (4.9) | 32 (4.6) | 37 (6.0) | 95 (5.2) | |||||
| 70–74 | 3 (1.2) | 10 (3.7) | 18 (2.6) | 18 (2.9) | 49 (2.7) | |||||
| 75–79 | 5 (2.0) | 11 (4.1) | 12 (1.7) | 21 (3.4) | 49 (2.7) | |||||
| 80–84 | 6 (2.4) | 4 (1.5) | 8 (1.1) | 11 (1.8) | 29 (1.6) | |||||
| 85 and over | 3 (1.2) | 3 (1.1) | 5 (0.7) | 5 (0.8) | 16 (0.9) | |||||
| Total | 249 | 268 | 702 | 619 | 1838 | |||||
First six months
The distribution of the number of cases by gender and quarterly periods of the years
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 2017 | Female | 33 (13.3) | 18 (7.2) | 30 (12.0) | 41 (16.5) | 122 (49.0) | 0.987 |
| Male | 36 (14.5) | 20 (8.0) | 30 (12.0) | 41 (16.5) | 127 (51.0) | ||
| Subtotal | 69 (27.7) | 38 (15.3) | 60 (24.1) | 82 (32.9) | 249 (100.0) | ||
| 2018 | Female | 17 (6.3) | 19 (7.1) | 20 (7.5) | 44 (16.4) | 100 (37.3) | 0.094 |
| Male | 47 (17.5) | 38 (14.2) | 30 (11.2) | 53 (19.8) | 168 (62.7) | ||
| Subtotal | 64 (23.9) | 57 (21.3) | 50 (18.7) | 97 (36.2) | 268 (100.0) | ||
| 2019 | Female | 56 (8.0) | 57 (8.1) | 70 (10.0) | 134 (19.1) | 317 (45.2) | 0.679 |
| Male | 81 (11.5) | 62 (8.8) | 80 (11.4) | 162 (23.1) | 385 (54.8) | ||
| Subtotal | 137 (19.5) | 119 (17.0) | 150 (21.4) | 296 (42.2) | 702 (100.0) | ||
| 2020 | Female | 150 (24.2) | 122 (19.7) | - | - | 272 (43.9) | 0.504 |
| Male | 182 (29.4) | 165 (26.7) | - | - | 347 (56.1) | ||
| Subtotal | 332 (53.6) | 287 (46.4) | - | - | 619 (100.0) |
Comparison of the first and second quarters
Fig. 1:The distribution of cases by months